A New Frontier

Deep Learning Diagnostic for Skin Malignancy

Bostel Technologies is a clinical-stage healthcare company that has developed Melody, a patent-pending unique Dual Deep Learning technology in order to facilitate the diagnosis of skin cancer by dermoscopy.

Skin cancers are the most frequent

About 1 million non-melanoma skin cancers and 288,000 malignant melanoma (MM) cancers occurred globally in 2018. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation Statistics, one in every five Americans will develop skin cancer in their lifetime.

An issue of growing importance

Longer living, lifestyle choice favoring sun exposure and depletion of the protective ozone layer are leading to a rapid increase in skin cancer. With a growing segment of the population aged 60 and above and thinning ozone layers, the number of Melanoma cases is projected by The WHO to increase by +30% by 2030

Significant unmet medical need

Skin cancer diagnosis is burdensome to both patients and health care professionals, resulting in a strong need for a more effective platform for skin cancer detection. Today, about 30 biopsies are performed to detect one melanoma.

How the Technology Works

Skin Cancer Diagnosis by Dual Deep Learning Technology

Clients

Bostel is Intended For

Hospitals, clinics and medical centers

Pharmacies and point of care locations

Healthcare professionals

Payers and healthcare insurers

Team of Experts

Pioneered by Leading Authorities

We have leveraged sonification and artificial intelligence to create a new diagnostic paradigm with clinically-proven sensitivity and specificity. This patent-pending platform will empower healthcare professionals to efficiently and effectively diagnose melanoma lesions using dermoscopy so they can focus on improving outcomes and helping their patients.

Contact Us